CRDF Q4 2019 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$133M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$92,577+18.7% YoY

Gross Profit

$92,577100.0% margin

Operating Income

-$4M-4633.2% margin

Net Income

-$4M-4582.7% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

+79.1%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$269,717

Balance Sheet

Total Assets

$13M

Total Liabilities

$6M

Stockholders' Equity

$7M

Cash & Equivalents

$10M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$92,577	$78,000	+18.7%
Gross Profit	$92,577	-$597M	+100.0%
Operating Income	-$4M	-$4M	-4.5%
Net Income	-$4M	-$4M	-2.0%

Revenue Segments

Royalty

$92,577100%